Cardinal Health Reports Strong Q3 Non-GAAP Results Amidst Goodwill Impairment and Ongoing Legal Challenges

summarizeSummary

Cardinal Health reported strong Q3 non-GAAP revenue and EPS growth, but GAAP results were significantly impacted by a $184 million goodwill impairment charge. The company also highlighted robust operating cash flow and ongoing share repurchases.

check_boxKey Events

• Q3 FY26 Non-GAAP Financial Performance

  Revenue increased 11% to $60.9 billion, and non-GAAP diluted EPS rose 35% to $3.17 for the three months ended March 31, 2026, driven by branded and specialty pharmaceutical sales and MSO acquisitions.

• Goodwill Impairment Charge

  A pre-tax non-cash goodwill impairment charge of $184 million was recognized in the Pharma segment related to the Navista & ION reporting unit, unfavorably impacting GAAP operating earnings by 30% and GAAP diluted EPS by 20% for the quarter.

• Strong Operating Cash Flow

  Net cash provided by operating activities significantly increased to $3.5 billion for the nine months ended March 31, 2026, compared to $877 million in the prior-year period.

• Capital Deployment and Share Repurchases

  The company deployed $1.0 billion for share repurchases under accelerated share repurchase programs during the nine months, with $1.8 billion remaining under the existing $3.5 billion program.

auto_awesomeAnalysis

This 10-Q filing provides comprehensive details following the pre-release of Q3 FY26 earnings. While non-GAAP results show robust growth driven by pharmaceutical sales and recent acquisitions, the report reveals a significant $184 million pre-tax goodwill impairment charge in the Pharma segment, which negatively impacted GAAP earnings and EPS. Investors should note the divergence between strong operational (non-GAAP) performance and the GAAP impact of this non-cash charge, alongside ongoing legal and tax contingencies. The substantial increase in operating cash flow and continued share repurchases are positive signals for liquidity and capital allocation.